These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20495919)

  • 1. Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen.
    Czejka M; Schueller J; Farkouh A; Gruenberger B; Scheithauer W
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):613-9. PubMed ID: 20495919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
    Farkouh A; Scheithauer W; Buchner P; Georgopoulos A; Schueller J; Gruenberger B; Czejka M
    Anticancer Res; 2014 Jul; 34(7):3669-73. PubMed ID: 24982385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
    Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
    Clin Cancer Res; 1998 Apr; 4(4):941-8. PubMed ID: 9563888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
    Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) with two different capecitabine/oxaliplatin dosage regimens.
    Farkouh A; Schueller J; Scheithauer W; Czejka M
    Int J Clin Pharmacol Ther; 2010 Jul; 48(7):487-8. PubMed ID: 20557855
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
    Ebi H; Sigeoka Y; Saeki T; Kawada K; Igarashi T; Usubuchi N; Ueda R; Sasaki Y; Minami H
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):205-11. PubMed ID: 15844007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer.
    Farid M; Chowbay B; Chen X; Tan SH; Ramasamy S; Koo WH; Toh HC; Choo SP; Ong SY
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):141-50. PubMed ID: 22648745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.
    Besnard T; Renée N; Etienne-Grimaldi MC; François E; Milano G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul; 870(1):117-20. PubMed ID: 18562256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.
    Di Desidero T; Orlandi P; Fioravanti A; Cremolini C; Loupakis F; Marmorino F; Antoniotti C; Masi G; Lonardi S; Bergamo F; Zagonel V; Falcone A; Bocci G
    Invest New Drugs; 2018 Aug; 36(4):709-714. PubMed ID: 29488048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and metabolism of irinotecan combined with capecitabine in patients with advanced colorectal cancer.
    Czejka M; Schueller J; Hauer K; Ostermann E
    Anticancer Res; 2005; 25(4):2985-90. PubMed ID: 16080556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer.
    Chachad S; Purandare S; Malhotra G; Naidu R
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):287-92. PubMed ID: 23090620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)].
    Minami H; Ebi H
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2053-7. PubMed ID: 16352928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
    Deng P; Ji C; Dai X; Zhong D; Ding L; Chen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():71-9. PubMed ID: 25808944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors.
    Saeki T; Takashima S; Terashima M; Satoh A; Toi M; Osaki A; Toge T; Ohno S; Nomura N; Fukuyama Y; Koizumi W; Taguchi T
    Int J Clin Oncol; 2005 Feb; 10(1):51-7. PubMed ID: 15729602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer.
    Hyodo I; Shirao K; Doi T; Hatake K; Arai Y; Yamaguchi K; Tamura T; Takemiya S; Takiuchi H; Nakagawa K; Mishima H
    Jpn J Clin Oncol; 2006 Jul; 36(7):410-7. PubMed ID: 16825251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between AUC of 5'-DFUR and toxicity of capecitabine, fluoropyrimidine carbamate analogs, and 5'-DFUR in monkeys, mice, and rats.
    Shindoh H; Kawashima A; Shishido N; Nakano K; Kobayashi K; Horii I
    J Toxicol Sci; 2006 Aug; 31(3):265-85. PubMed ID: 16960436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity.
    Guichard SM; Macpherson JS; Mayer I; Reid E; Muir M; Dodds M; Alexander S; Jodrell DI
    Eur J Cancer; 2008 Jan; 44(2):310-7. PubMed ID: 18077151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
    Sekido M; Fujita KI; Kubota Y; Ishida H; Takahashi T; Ohkuma R; Tsunoda T; Ishikawa F; Shibanuma M; Sasaki Y
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1127-1135. PubMed ID: 30972456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030).
    Louie SG; Ely B; Lenz HJ; Albain KS; Gotay C; Coleman D; Raghavan D; Shields AF; Gold PJ; Blanke CD
    Br J Cancer; 2013 Oct; 109(7):1744-9. PubMed ID: 24022189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.